Immunomedics Announces Presentations at the 16th Congress of the European Hematology Association

/ Source: GlobeNewswire

MORRIS PLAINS, N.J., June 2, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 presentations will be given at the 16th Congress of the European Hematology Association, scheduled for June 9 – 12, 2011, in London, United Kingdom.

The title of the presentations together with the abstract number and schedule are listed below:

  • "Treatment of B-cell malignancies with epratuzumab anti-CD22-SN-38 conjugates alone and combined with veltuzumab anti-CD20 antibody therapy" [Abstract No. 0389, Session: Novel therapeutic, targeted therapies and gene therapy, Friday, June 10, 5:45 p.m. – 7:00 p.m.]
  • "Crosslinking CD74 and CD20 with novel bispecific anti-CD74/CD20 antibodies induces potent cytotoxicity in mantle cell lymphoma lines" [Abstract No. 0477, Session: Non-Hodgkin Lymphoma – From biology to therapy, Saturday, June 11, 8:45 a.m. – 9:00 a.m., Hall S4]
  • "Subcutaneous injections of low-dose anti-CD20 veltuzumab for patients with relapsed immune thrombocytopenia (ITP)" [Abstract No. 0527, Session: Platelets and bleeding disorders, Saturday, June 11, 4:30 p.m. – 4:45 p.m., Platinum Suite 1]
  • "Anti-HLA-DR-targeting immunocytokine comprising tetrameric interferon-alpha-2b has potent in vitro and in vivo activity with various hematological cancers" [Abstract No. 0644, Session: Cellular immunotherapy and vaccination, Saturday, June 11, 5:30 p.m. – 6:45 p.m.]

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 178 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at .  The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Dr. Chau Cheng Director, Investor Relations & Grant Management (973) 605-8200, extension 123